Peter Jones - Concepedia

Author

Peter Jones

Pfizer (United Kingdom)ORCID

Also Known As

P Jones, P. JONES, P. Jones, P. S. Jones, PETER JONES, Peter Jones, Peter S Jones, Peter S. Jones, Peter Stevens Jones

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United Kingdom)University of Utah Pfizer (United States)Intermountain Healthcare Intermountain Medical Center

About

Peter Jones is an author at Pfizer (United Kingdom) specializing in drug discovery, medicine, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	510
2	Natural Sciences	5	5	505
3	Biochemistry	4	4	488
4	Engineering	2	2	50
5	Education	1	1	10

Peter Jones

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery David C. Pryde, Deepak Dalvie, Qiyue Hu, Journal of Medicinal Chemistry Altmetric Attention ScorePharmaceutical ChemistryRedox BiologyOxidative StressMolecular Pharmacology	2010	342
Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay J. Perry Hall, Amy Brault, Fabien Vincent, PLoS ONE	2017	157
Impact of Implementing Antibiotic Stewardship Programs in 15 Small Hospitals: A Cluster-Randomized Intervention Edward Stenehjem, Adam L. Hersh, Whitney R. Buckel, Clinical Infectious Diseases	2018	72
Antibiotic Use in Small Community Hospitals Edward Stenehjem, Adam L. Hersh, Xiaoming Sheng, Clinical Infectious Diseases	2016	57
On the choice of Lewis acids for the Prins reaction; two total syntheses of (±)-Civet Freda K. I. Chio, Julie Warne, Damien Francis Christopher Gough, Tetrahedron BiochemistryPrins ReactionNatural SciencesLewis AcidsOrganic Chemistry	2011	55
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin Peter Jones, Richard Storer, Yogesh Sabnis, Journal of Medicinal Chemistry Drug TargetInflammatory Lung DiseaseLung InflammationAtp Binding SitePharmacotherapy	2016	53
Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target Duncan C. Miller, Graham Lunn, Peter Jones, MedChemComm Chemical BiologyMolecular PropertiesDrug TargetBiochemistryMedicine	2012	51
Asymmetric Synthesis of α-Aryl Amino Acids; Aryne-Mediated Diastereoselective Arylation Elizabeth P. Jones, Peter Jones, Anthony G. M. Barrett Organic Letters Substituted ArylglycinesEngineeringBiochemistryNatural SciencesDiversity-oriented Synthesis	2011	40
The role of patients in pressure injury prevention: a survey of acute care patients Elizabeth McInnes, Wendy Chaboyer, Edel Murray, BMC Nursing	2014	39
Discovery of 3-Cyano- <i>N</i> -(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 <i>H</i> -pyrrolo[2,3- <i>b</i> ]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist Mark E. Schnute, Mattias Wennerstål, Jennifer Alley, Journal of Medicinal Chemistry	2018	32

Page 1